These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 21471980)

  • 21. 5-
    Kato A; Nakagome I; Kanekiyo U; Lu TT; Li YX; Yoshimura K; Kishida M; Shinzawa K; Yoshida T; Tanaka N; Jia YM; Nash RJ; Fleet GWJ; Yu CY
    J Med Chem; 2022 Feb; 65(3):2329-2341. PubMed ID: 35072486
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hydrophilic iminosugar active-site-specific chaperones increase residual glucocerebrosidase activity in fibroblasts from Gaucher patients.
    Chang HH; Asano N; Ishii S; Ichikawa Y; Fan JQ
    FEBS J; 2006 Sep; 273(17):4082-92. PubMed ID: 16934036
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chaperone activity of bicyclic nojirimycin analogues for Gaucher mutations in comparison with N-(n-nonyl)deoxynojirimycin.
    Luan Z; Higaki K; Aguilar-Moncayo M; Ninomiya H; Ohno K; García-Moreno MI; Ortiz Mellet C; García Fernández JM; Suzuki Y
    Chembiochem; 2009 Nov; 10(17):2780-92. PubMed ID: 19830760
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biochemical and pharmacological characterization of different recombinant acid alpha-glucosidase preparations evaluated for the treatment of Pompe disease.
    McVie-Wylie AJ; Lee KL; Qiu H; Jin X; Do H; Gotschall R; Thurberg BL; Rogers C; Raben N; O'Callaghan M; Canfield W; Andrews L; McPherson JM; Mattaliano RJ
    Mol Genet Metab; 2008 Aug; 94(4):448-455. PubMed ID: 18538603
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers.
    Raben N; Fukuda T; Gilbert AL; de Jong D; Thurberg BL; Mattaliano RJ; Meikle P; Hopwood JJ; Nagashima K; Nagaraju K; Plotz PH
    Mol Ther; 2005 Jan; 11(1):48-56. PubMed ID: 15585405
    [TBL] [Abstract][Full Text] [Related]  

  • 26. p.[G576S; E689K]: pathogenic combination or polymorphism in Pompe disease?
    Kroos MA; Mullaart RA; Van Vliet L; Pomponio RJ; Amartino H; Kolodny EH; Pastores GM; Wevers RA; Van der Ploeg AT; Halley DJ; Reuser AJ
    Eur J Hum Genet; 2008 Aug; 16(8):875-9. PubMed ID: 18301443
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glycogen stored in skeletal but not in cardiac muscle in acid alpha-glucosidase mutant (Pompe) mice is highly resistant to transgene-encoded human enzyme.
    Raben N; Jatkar T; Lee A; Lu N; Dwivedi S; Nagaraju K; Plotz PH
    Mol Ther; 2002 Nov; 6(5):601-8. PubMed ID: 12409258
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Species-specific differences in the processing of acid α-glucosidase are due to the amino acid identity at position 201.
    Moreland RJ; Higgins S; Zhou A; VanStraten P; Cauthron RD; Brem M; McLarty BJ; Kudo M; Canfield WM
    Gene; 2012 Jan; 491(1):25-30. PubMed ID: 21963446
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Promising results of the chaperone effect caused by imino sugars and aminocyclitol derivatives on mutant glucocerebrosidases causing Gaucher disease.
    Sánchez-Ollé G; Duque J; Egido-Gabás M; Casas J; Lluch M; Chabás A; Grinberg D; Vilageliu L
    Blood Cells Mol Dis; 2009; 42(2):159-66. PubMed ID: 19167250
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neonatal gene transfer using lentiviral vector for murine Pompe disease: long-term expression and glycogen reduction.
    Kyosen SO; Iizuka S; Kobayashi H; Kimura T; Fukuda T; Shen J; Shimada Y; Ida H; Eto Y; Ohashi T
    Gene Ther; 2010 Apr; 17(4):521-30. PubMed ID: 20033064
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Introduction of
    Kato A; Nakagome I; Yoshimura K; Kanekiyo U; Kishida M; Shinzawa K; Lu TT; Li YX; Nash RJ; Fleet GWJ; Tanaka N; Yu CY
    Org Biomol Chem; 2022 Sep; 20(36):7250-7260. PubMed ID: 35838176
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term enzyme replacement therapy for pompe disease with recombinant human alpha-glucosidase derived from chinese hamster ovary cells.
    Rossi M; Parenti G; Della Casa R; Romano A; Mansi G; Agovino T; Rosapepe F; Vosa C; Del Giudice E; Andria G
    J Child Neurol; 2007 May; 22(5):565-73. PubMed ID: 17690063
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of a novel noniminosugar acid α glucosidase chaperone series.
    Xiao J; Westbroek W; Motabar O; Lea WA; Hu X; Velayati A; Zheng W; Southall N; Gustafson AM; Goldin E; Sidransky E; Liu K; Simeonov A; Tamargo RJ; Ribes A; Matalonga L; Ferrer M; Marugan JJ
    J Med Chem; 2012 Sep; 55(17):7546-59. PubMed ID: 22834902
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and metabolic correction of pompe disease by enzyme therapy in acid maltase-deficient quail.
    Kikuchi T; Yang HW; Pennybacker M; Ichihara N; Mizutani M; Van Hove JL; Chen YT
    J Clin Invest; 1998 Feb; 101(4):827-33. PubMed ID: 9466978
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthetic 1-deoxynojirimycin N-substituted peptides offer prolonged disruption to N-linked glycan processing.
    Aguilar AL; Escribano J; Wentworth P; Butters TD
    ChemMedChem; 2014 Dec; 9(12):2809-13. PubMed ID: 25352425
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Strategy for Designing Selective Lysosomal Acid α-Glucosidase Inhibitors: Binding Orientation and Influence on Selectivity.
    Kato A; Nakagome I; Hata M; Nash RJ; Fleet GWJ; Natori Y; Yoshimura Y; Adachi I; Hirono S
    Molecules; 2020 Jun; 25(12):. PubMed ID: 32575625
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glycogen Storage Disease type II: genetic and biochemical analysis of novel mutations in infantile patients from Turkish ancestry.
    Hermans MM; Kroos MA; Smeitink JA; van der Ploeg AT; Kleijer WJ; Reuser AJ
    Hum Mutat; 1998; 11(3):209-15. PubMed ID: 9521422
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular and functional characterization of eight novel GAA mutations in Italian infants with Pompe disease.
    Pittis MG; Donnarumma M; Montalvo AL; Dominissini S; Kroos M; Rosano C; Stroppiano M; Bianco MG; Donati MA; Parenti G; D'Amico A; Ciana G; Di Rocco M; Reuser A; Bembi B; Filocamo M
    Hum Mutat; 2008 Jun; 29(6):E27-36. PubMed ID: 18429042
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation of acid alpha-glucosidase and glycogen content in skin fibroblasts with age of onset in Pompe disease.
    Umapathysivam K; Hopwood JJ; Meikle PJ
    Clin Chim Acta; 2005 Nov; 361(1-2):191-8. PubMed ID: 15993875
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Update of the Pompe disease mutation database with 107 sequence variants and a format for severity rating.
    Kroos M; Pomponio RJ; van Vliet L; Palmer RE; Phipps M; Van der Helm R; Halley D; Reuser A;
    Hum Mutat; 2008 Jun; 29(6):E13-26. PubMed ID: 18425781
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.